1GDA Stock Overview
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Zevra Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.35 |
52 Week High | US$6.45 |
52 Week Low | US$3.82 |
Beta | 1.82 |
1 Month Change | -13.71% |
3 Month Change | 22.15% |
1 Year Change | 6.66% |
3 Year Change | -31.41% |
5 Year Change | -77.56% |
Change since IPO | -98.09% |
Recent News & Updates
Recent updates
Shareholder Returns
1GDA | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -2.7% | 3.0% | 1.3% |
1Y | 6.7% | -25.6% | 6.4% |
Return vs Industry: 1GDA exceeded the German Pharmaceuticals industry which returned -25.6% over the past year.
Return vs Market: 1GDA matched the German Market which returned 6.4% over the past year.
Price Volatility
1GDA volatility | |
---|---|
1GDA Average Weekly Movement | 9.1% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1GDA has not had significant price volatility in the past 3 months.
Volatility Over Time: 1GDA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 34 | Neil McFarlane | https://zevra.com |
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).
Zevra Therapeutics, Inc. Fundamentals Summary
1GDA fundamental statistics | |
---|---|
Market cap | €220.68m |
Earnings (TTM) | -€36.86m |
Revenue (TTM) | €15.30m |
14.4x
P/S Ratio-6.0x
P/E RatioIs 1GDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1GDA income statement (TTM) | |
---|---|
Revenue | US$16.56m |
Cost of Revenue | US$1.09m |
Gross Profit | US$15.47m |
Other Expenses | US$55.39m |
Earnings | -US$39.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -0.96 |
Gross Margin | 93.43% |
Net Profit Margin | -241.00% |
Debt/Equity Ratio | 65.0% |
How did 1GDA perform over the long term?
See historical performance and comparison